Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0X2XF
|
||||
Former ID |
DNC001122
|
||||
Drug Name |
Piboserod
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Atrial fibrillation [ICD9: 272, 427.31; ICD10:E78, I48] | Phase 2 | [1], [2] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C22H31N3O2
|
||||
InChI |
InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26)
|
||||
InChIKey |
KVCSJPATKXABRQ-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 290815-26-8
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 4 receptor | Target Info | Antagonist | [3] | |
KEGG Pathway | Calcium signaling pathway | ||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Serotonergic synapse | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
5HT4 type receptor mediated signaling pathway | |||||
PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | ||||
Reactome | Serotonin receptors | ||||
G alpha (s) signalling events | |||||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT00421746) A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure. U.S. National Institutes of Health. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 225). | ||||
REF 3 | Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.